바이오테크 보도자료
-
- Asia Specific Biotechnology Instruments Market Is Poised To Exceed USD 40 Bn by 2032; R&D Arms of Major Multinational Pharmaceutical Corporations Fuels The Market: Report by Fact.MR
- The Biotechnology Instruments Market revenues were estimated at USD 46.1 Bn in 2021 and is anticipated to grow at a CAGR of 16.4% from 2022-2032, according to a recently published Fact.MR report. By the end ...
- 2022년 06월 22일
-
- Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
- Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared with pl...
- 2022년 06월 22일
-
- Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
- Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the ASEAN Aca...
- 2022년 06월 21일
-
- Companies in the Global Omics Based Clinical Trials Market Expedite Product Innovations to Stay at Forefront; Expected Sales to Reach USD 61.7 Bn By 2032: Fact.MR’s Study
- The Omics Based Clinical Trials Market revenues were estimated at USD 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2032, according to a recently published Fact.MR report. By the ...
- 2022년 06월 21일
-
- AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting
- AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology A...
- 2022년 06월 21일
-
- Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
- Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, he...
- 2022년 06월 20일
-
- IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference
- Today’s decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and development and...
- 2022년 06월 17일
-
- Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
- Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide today announced that its ordinary shares and warrants will begin trading on...
- 2022년 06월 16일
-
- Saint-Gobain Bioprocess Solutions Business Announces C-Flex® Production Capability in Suwa, Japan
- Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex® TPE tubing for use in bioprocessing. The capacity addition in Suwa is part of...
- 2022년 06월 16일
전시회
